Caution in interpretation of abnormal carbon monoxide diffusion capacity in COVID-19 patients
- PMID: 33154026
- PMCID: PMC7651835
- DOI: 10.1183/13993003.03263-2020
Caution in interpretation of abnormal carbon monoxide diffusion capacity in COVID-19 patients
Abstract
Reduced KCO in discharged patients with COVID-19 suggests persistent abnormalities in gas exchange. Further research is required to understand why.
Conflict of interest statement
Conflict of interest: D.G. Chapman has nothing to disclose. Conflict of interest: T. Badal has nothing to disclose. Conflict of interest: G.G. King reports personal fees, non-financial support and other from AstraZeneca, Boehringer Ingelheim, GSK, Menarini, MundiPharma and Novartis (consultancy fees for talks, chairmanship, advisory boards and conference sponsorship), unrestricted research grants from NHMRC, Boehringer Ingelheim, CycloPharma, GlaxoSmithKline, Menarini, MundiPharma, philanthropic individuals and societies, and non-financial support from Restech (research collaboration and in-kind support), outside the submitted work. Conflict of interest: C. Thamrin has nothing to disclose.
Figures
Comment on
-
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.Eur Respir J. 2020 Jun 18;55(6):2001217. doi: 10.1183/13993003.01217-2020. Print 2020 Jun. Eur Respir J. 2020. PMID: 32381497 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical